855f0a82-04de-485d-9613-5ccf08074069
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.400
- COAGULATION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_DN+0.400
- APICAL_SURFACE+0.300
- BILE_ACID_METABOLISM+0.300
- COMPLEMENT+0.300
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V2-0.600
- MITOTIC_SPINDLE-0.500
- MYC_TARGETS_V1-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- DNA_REPAIR-0.400
- MTORC1_SIGNALING-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- PROTEIN_SECRETION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NYS8TRCB | low-grade glioma | — | 0.895 |
| 2 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.894 |
| 3 | SRR8613709 | — | A | 0.889 |
| 4 | ERR2208952 | — | — | 0.889 |
| 5 | SRR1468574 | GTEX | — | 0.887 |
| 6 | TCGA-F7-A50G-01A-11R-A266-07 | — | — | 0.886 |
| 7 | MDT-AP-1152 | Med | Medulloblastoma | 0.885 |
| 8 | MDT-AP-2283 | Med | Medulloblastoma | 0.885 |
| 9 | TCGA-69-8453-01A-12R-2326-07 | — | cohortA1 | 0.877 |
| 10 | MDT-AP-2579 | Med | Medulloblastoma | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |